Format

Send to

Choose Destination
BMC Vet Res. 2015 Jun 11;11:132. doi: 10.1186/s12917-015-0422-9.

Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.

Author information

1
Clinic for Horses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. kathrin.maehlmann@vetsuisse.unibe.ch.
2
Clinic for Horses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. karsten.feige@tiho-hannover.de.
3
Mologen AG, Berlin, Germany. juhls@mologen.com.
4
Mologen AG, Berlin, Germany. endmann@mologen.com.
5
Immunology Unit, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. hans-joachim.schuberth@tiho-hannover.de.
6
Mologen AG, Berlin, Germany. Oswald@mologen.com.
7
Clinic for Horses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. maren.hellige@tiho-hannover.de.
8
Institute for Veterinary Epidemiology and Biostatistics, Free University of Berlin, Berlin, Germany. marcus.doherr@fu-berlin.de.
9
Clinic for Horses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. jessika.cavalleri@tiho-hannover.de.

Abstract

BACKGROUND:

Equine melanoma has a high incidence in grey horses. Xenogenic DNA vaccination may represent a promising therapeutic approach against equine melanoma as it successfully induced an immunological response in other species suffering from melanoma and in healthy horses. In a clinical study, twenty-seven, grey, melanoma-bearing, horses were assigned to three groups (n = 9) and vaccinated on days 1, 22, and 78 with DNA vectors encoding for equine (eq) IL-12 and IL-18 alone or in combination with either human glycoprotein (hgp) 100 or human tyrosinase (htyr). Horses were vaccinated intramuscularly, and one selected melanoma was locally treated by intradermal peritumoral injection. Prior to each injection and on day 120, the sizes of up to nine melanoma lesions per horse were measured by caliper and ultrasound. Specific serum antibodies against hgp100 and htyr were measured using cell based flow-cytometric assays. An Analysis of Variance (ANOVA) for repeated measurements was performed to identify statistically significant influences on the relative tumor volume. For post-hoc testing a Tukey-Kramer Multiple-Comparison Test was performed to compare the relative volumes on the different examination days. An ANOVA for repeated measurements was performed to analyse changes in body temperature over time. A one-way ANOVA was used to evaluate differences in body temperature between the groups. A p-value < 0.05 was considered significant for all statistical tests applied.

RESULTS:

In all groups, the relative tumor volume decreased significantly to 79.1 ± 26.91% by day 120 (p < 0.0001, Tukey-Kramer Multiple-Comparison Test). Affiliation to treatment group, local treatment and examination modality had no significant influence on the results (ANOVA for repeated measurements). Neither a cellular nor a humoral immune response directed against htyr or hgp100 was detected. Horses had an increased body temperature on the day after vaccination.

CONCLUSIONS:

This is the first clinical report on a systemic effect against equine melanoma following treatment with DNA vectors encoding eqIL12 and eqIL18 and formulated with a transfection reagent. Addition of DNA vectors encoding hgp100 respectively htyr did not potentiate this effect.

PMID:
26063232
PMCID:
PMC4464139
DOI:
10.1186/s12917-015-0422-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center